The latest price target for Galmed Pharmaceuticals (NASDAQ:GLMD) was reported by Maxim Group on April 4, 2025. The analyst firm set a price target for $0.00 expecting GLMD to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Galmed Pharmaceuticals (NASDAQ:GLMD) was provided by Maxim Group, and Galmed Pharmaceuticals downgraded their hold rating.

The last upgrade for Galmed Pharmaceuticals Ltd happened on July 24, 2023 when Maxim Group raised their price target to $4. Maxim Group previously had a hold for Galmed Pharmaceuticals Ltd.

The last downgrade for Galmed Pharmaceuticals Ltd happened on April 4, 2025 when Maxim Group changed their price target from N/A to N/A for Galmed Pharmaceuticals Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on April 4, 2025 so you should expect the next rating to be made available sometime around April 4, 2026.

While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a downgraded with a price target of $0.00 to $0.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $1.35, which is out of the analyst’s predicted range.